FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
Acura Pharmaceuticals’ stock fell 11% May 28 after the company revealed that FDA advised an abuse liability study for its hydrocodone/acetaminophen product would not support an abuse liability claim.